Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/03/21/2850104/0/en/Immatics-Announces-Full-Year-2023-Financial-Results-and-Corporate-Update.html
https://www.globenewswire.com//news-release/2024/01/18/2811206/0/en/Immatics-Announces-Pricing-of-175-Million-Public-Offering.html
https://www.globenewswire.com//news-release/2024/01/17/2811114/0/en/Immatics-Announces-Proposed-Public-Offering.html
https://www.globenewswire.com//news-release/2023/11/14/2779897/0/en/Immatics-Announces-Third-Quarter-2023-Financial-Results-and-Business-Update.html
https://www.globenewswire.com//news-release/2023/11/08/2776060/0/en/Immatics-Reports-Interim-Clinical-Data-from-ACTengine-IMA203-and-IMA203CD8-TCR-T-Monotherapies-Targeting-PRAME-in-an-Ongoing-Phase-1-Trial.html
https://www.globenewswire.com//news-release/2023/10/24/2765460/0/en/Immatics-Receives-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-ACTengine-IMA203-TCR-T-Monotherapy.html
https://www.biospace.com/article/moderna-immatics-ink-potential-1-8b-oncology-deal-including-cancer-vaccines/
https://www.globenewswire.com//news-release/2023/08/17/2727115/0/en/Immatics-Announces-Second-Quarter-2023-Financial-Results-and-Business-Update.html
https://www.globenewswire.com/news-release/2023/08/10/2722469/0/en/Immatics-Initiates-Phase-1-2-Clinical-Trial-to-Evaluate-PRAME-TCR-Bispecific-IMA402-in-Patients-with-Advanced-Solid-Tumors.html
https://www.globenewswire.com/news-release/2023/07/24/2709406/0/en/Immatics-Announces-35-Million-Equity-Investment-from-Bristol-Myers-Squibb.html